Directed Energy Therapeutics develops tumor-activated, peptide-based bioelectric medicines that modulate ion channels and membrane potential to disrupt solid tumors and sensitize them to immune clearance. Our lead program targets pancreatic ductal adenocarcinoma (PDAC) using precision tumor homing and conditional activation to improve therapeutic index while enabling deep tumor penetration and microenvironment remodeling. The Arcwave platform translates bioelectric control of cell state into drug-like, modular therapeutics.